Considering the upregulation of LOX during tumor hypoxia, reductively activatable prodrugs of βAPN have been developed, which were shown to be capable of inhibiting the invasion of MDA-MB-231 breast tumor cells under hypoxic conditions in vitro (Granchi et al., 2009). The gene discussed is LOX; the disease is neoplasm.